白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
Journal of Leukemia & Lymphoma
2015年
9期
566-569
,共4页
弥漫大B细胞淋巴瘤%年轻高危%预后%治疗
瀰漫大B細胞淋巴瘤%年輕高危%預後%治療
미만대B세포림파류%년경고위%예후%치료
Diffuse large B-cell lymphoma%Young patients%High-risk%Prognosis%Treatment
弥漫大B细胞淋巴瘤(DLBCL)是成年人淋巴瘤中最常见的一种类型,约占非霍奇金淋巴瘤(NHL)的30％～ 40％.年轻高危DLBCL患者是临床预后不良的一组特殊人群,目前在临床实践中尚无标准治疗方案,常规化疗、联合利妥昔单抗的R-CHOP、R-CHOP样方案、大剂量化疗及自体造血干细胞移植并未完全扭转其预后不良的现实.文章就年轻高危DLBCL患者的治疗现状及未来的治疗方向进行综述.
瀰漫大B細胞淋巴瘤(DLBCL)是成年人淋巴瘤中最常見的一種類型,約佔非霍奇金淋巴瘤(NHL)的30％～ 40％.年輕高危DLBCL患者是臨床預後不良的一組特殊人群,目前在臨床實踐中尚無標準治療方案,常規化療、聯閤利妥昔單抗的R-CHOP、R-CHOP樣方案、大劑量化療及自體造血榦細胞移植併未完全扭轉其預後不良的現實.文章就年輕高危DLBCL患者的治療現狀及未來的治療方嚮進行綜述.
미만대B세포림파류(DLBCL)시성년인림파류중최상견적일충류형,약점비곽기금림파류(NHL)적30％～ 40％.년경고위DLBCL환자시림상예후불량적일조특수인군,목전재림상실천중상무표준치료방안,상규화료、연합리타석단항적R-CHOP、R-CHOP양방안、대제양화료급자체조혈간세포이식병미완전뉴전기예후불량적현실.문장취년경고위DLBCL환자적치료현상급미래적치료방향진행종술.
Diffuse large B-cell lymphoma (DLBCL) is the most common adult lymphoid malignancy accounting for 30 ％-40 ％ of all non-Hodgkin lymphoma (NHL).Young patients with high-risk DLBCL as a special group with poor clinical prognosis still can not receive standard treatment protocols in clinical practice at present.Conventional chemotherapy, combination of rituximab (R) to conventional CHOP chemotherapy, R-CHOP-like protocol, high-dose chemotherapy and autologous hematopoietic stem cell transplantation have not fully reversed the poor prognosis.This review focuses on the recent advances and future direction in the treatment of the young patients with high-risk DLBCL.
